R&D channel feed

Al­ny­lam shoots for a speedy FDA OK af­ter their next shot at field­ing a pricey rare dis­ease drug hits PhI­II goal

7 years ago

J&J has de­cid­ed — phar­ma gi­ant dumps its de­vel­op­ment deal on Geron’s ime­tel­stat, shat­ter­ing shares

7 years ago

Eli Lil­ly picks up an oral GLP-1 di­a­betes drug from a big Roche sub for $50M in cash-plus deal — and it’s not a pep­tide

7 years ago
Pharma

Aldeyra shares soar on pos­i­tive PhII dry eye da­ta — but lose some steam on sec­ond look

7 years ago

GSK's vac­cine arm lays claim to a ma­jor break­through on tu­ber­cu­lo­sis

7 years ago

Roche's IM­pow­er133 of­fers a glimpse at rare progress in fight against small cell lung can­cer

7 years ago

Re­searchers point to R&D treaty to spur new in­fec­tious dis­ease treat­ments

7 years ago
Pharma

As­traZeneca spells out a ma­jor drop in the risk of death for stage 3 NSCLC pa­tients tak­ing Imfinzi — and why that's im­por­tant

7 years ago

Cash-strapped Gem­phire lets go of five staffers as it con­tends with a clin­i­cal hold

7 years ago

Chop­ping close to home, No­var­tis out­lines plans to ax or move about 2,600 more jobs in an­oth­er wave of glob­al re­struc­tur­ing

7 years ago

Alex­ion’s Soliris wows in rare dis­ease PhI­II tri­al, open­ing up a new fran­chise worth $500M-$700M

7 years ago

Trail­ing ri­vals, As­traZeneca of­fers a hit and a miss on key car­dio study for SGLT2 di­a­betes drug Farx­i­ga

7 years ago

Amarin scores a big win for its car­dio out­comes study on Vas­cepa — stock races high­er as an­a­lysts ap­plaud

7 years ago

Park­er col­lab­o­ra­tor Tes­sa al­lies with St. Jude, launch­es a new T cell pro­gram for pe­di­atric brain can­cer

7 years ago
Discovery

GTx ex­ec­s' sole drug fails the lead in­di­ca­tion study in a painful set­back -- shares smashed

7 years ago

Dis­miss­ing crit­i­cal re­ports on pa­tient deaths, FDA says safe­ty/ef­fec­tive­ness of Nu­plazid holds up un­der re­view

7 years ago
Pharma

A snap­shot of up­beat PhII NASH da­ta — from a very small tri­al — trig­gers a fren­zy for Viking’s stock

7 years ago

Unit­ed’s Mar­tine Roth­blatt en­dors­es a biotech uni­corn’s CEO and antes up for US rights to an IPF drug

7 years ago
Pharma

Servi­er shrugs off a mul­ti­mil­lion-dol­lar in­vest­ment, aban­don­ing a failed MS drug de­vel­oped by GeNeu­ro

7 years ago
Pharma

Al­ler­gan, So­sei halt glob­al de­vel­op­ment for Alzheimer’s drug fol­low­ing tox­ic re­ac­tion in a non-hu­man pri­mate

7 years ago

No­vo Nordisk is whack­ing 400 R&D jobs, re­or­ga­niz­ing glob­al R&D ops around 4 “trans­for­ma­tion­al” units

7 years ago
Pharma

Can­cer Re­search UK launch­es new Lon­don Cen­tre, in­fus­ing £14M in­to bio­ther­a­peu­tics work from lead­ing in­sti­tutes

7 years ago
Pharma

Af­ter back-to-back tri­al flops, Realm slash­es its staff, halts re­search work and pon­ders a fire sale

7 years ago

As­traZeneca's res­pi­ra­to­ry group spells out some set­backs in its lat­est PhI­II read­out for GSK COPD ri­val PT010

7 years ago
First page Previous page 260261262263264265266 Next page Last page
A service from the Financial Times